Urethral cancer

Urethral cancer is cancer originating from the urethra. Cancer in this location is rare, and the most common type is papillary transitional cell carcinoma.[1] The most common site of urethral cancer is the bulbomembranous urethra.

This article is about cancer of the urethra. For cancer of the ureter, see Ureteral cancer.

Urethral cancer
Micrograph of a urethral cancer, urothelial cell carcinoma, found on a prostate core biopsy. H&E stain.
SpecialtyOncology

Signs and symptoms

Symptoms that may be caused by urethral cancer include: Bleeding from the urethra or blood in the urine, Weak or interrupted flow of urine, Urination occurs often, painful urination, inability to pass urine, A lump or thickness in the perineum or penis, Discharge from the urethra, Enlarged lymph nodes or pain in the groin or vaginal area.

Risk factors

The main medical risk factors are having bladder cancer or having conditions that cause chronic inflammation in the urethra. People over the age of 60 and white women have the highest risks.

Diagnosis

Diagnosis is established by transurethral biopsy. Types of urethral cancer include transitional cell carcinoma, squamous cell carcinoma, adenocarcinoma, and melanoma.

Treatment

Surgery is the most common treatment for cancer of the urethra. One of the following types of surgery may be done: Open excision, Electro-resection with flash, Laser surgery, Cystourethrectomy, Cystoprostatectomy, Anterior body cavity, or Incomplete or basic penectomy surgery.

Chemotherapy is sometimes used to destroy urethral cancer cells. It is a systemic urethral cancer treatment (i.e., destroys urethral cancer cells throughout the body) that is administered orally or intravenously. Medications are often used in combination to destroy urethral cancer that has metastasized. Commonly used drugs include cisplatin, vincristine, and methotrexate.

Side effects include anemia (causing fatigue, weakness), nausea and vomiting, loss of appetite, hair loss, mouth sores, increased risk for infection, shortness of breath, or excessive bleeding and bruising.[2]

See also

References
  1. Ries, LAG; Young, JL; Keel, GE; Eisner, MP; Lin, YD; Horner, M-J, eds. (2007). "SEER Survival Monograph: Cancer Survival Among Adults: US SEER Program, 1988-2001, Patient and Tumor Characteristics". SEER Program. Bethesda, MD: National Cancer Institute. pp. 251–262. Archived from the original on 10 October 2013. Retrieved 18 October 2013. |contribution= ignored (help)
  2. Urethral Cancer Treatment
Classification
External resources
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.